• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Acasti Pharma Inc.

    10/8/24 7:22:41 AM ET
    $ACST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACST alert in real time by email
    S-8 1 ef20036399_s8.htm S-8
    As filed with the Securities and Exchange Commission on October 8, 2024

    Registration No. 333-


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    FORM S-8
     
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933


     
    ACASTI PHARMA INC.
    (Exact name of Registrant as specified in its charter)



    Delaware
     
    98-1359336
    (State or other jurisdiction of incorporation or organization)
     
    (I.R.S. Employer Identification Number)

    103 Carnegie Center, Suite 300
    Princeton, New Jersey
     
    08540
    (Address of Principal Executive Offices)
     
    (Zip Code)

    ACASTI PHARMA INC. 2024 EQUITY INCENTIVE PLAN
    (Full title of the plan)


    Prashant Kohli
    Chief Executive Officer
    Acasti Pharma Inc.
    103 Carnegie Center, Suite 300
    Princeton, New Jersey 08540
    (Name and Address of Agent for Service)
     
    (609) 322-1602
    (Telephone Number, Including Area Code, of Agent For Service)

    Copy to:
    Steven J. Abrams
    Hogan Lovells US LLP
    1735 Market Street, 23rd Floor
    Philadelphia, PA 19103
    (267) 675-4600

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer
    ☐
    Accelerated filer
    ☐


       
    Non-accelerated filer
    ☒
    Smaller reporting company
    ☒


       


    Emerging growth company
    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐
     


    PART I
     
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
     
    This Registration Statement (the “Registration Statement”) on Form S-8 is being filed with the Securities and Exchange Commission (the “Commission”) for the purpose of registering the offer and issuance of shares of common stock, par value $0.0001 per share (the “Common Stock”) of Acasti Pharma Inc. (the “Registrant,” or the “Company”) to certain directors, employees and consultants of the Company and/or its subsidiaries under the Company’s 2024 Equity Incentive Plan (as it may be amended from time to time, the “2024 Equity Incentive Plan”).
     
    Pursuant to Part I of Form S-8, the information specified under Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to participants in the 2024 Equity Incentive Plan as specified by Rule 428(b)(1) under the Securities Act. Such documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Form S-8, when taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act. Such documents are not required to be, and are not, filed with the Commission either as part of this Registration Statement or as a prospectus or prospectus supplement pursuant to Rule 424 under the Securities Act.
     
    PART II
     
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
     
    Item 3.
    Incorporation of Documents by Reference.
     
    The following documents filed by the Company with the Commission are incorporated by reference herein:

      (a)
    The Company’s Annual Report on Form 10-K for the year ended March 31, 2024, filed with the Commission on June 21, 2024;

      (b)
    The Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the Commission on August 9, 2024;

      (c)
    The Company’s Current Reports on Form 8-K (other than portions thereof furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits accompanying such reports that relate to such items), filed with the Commission on June 27, 2024, August 16, 2024, September 25, 2024, September 30, 2024 and October 7, 2024; and

      (d)
    The description of the Company’s common stock included in the final prospectus dated August 7, 2024, filed with the Commission on August 7, 2024 pursuant to Rule 424(b)(3).

    All reports and other documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), but prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such reports and documents, except for the documents, or portions thereof, that are “furnished” rather than filed with the Commission; provided, however, that documents or portions thereof that are furnished and not filed in accordance with the rules of  the Commission shall not be deemed to be incorporated by reference herein.
     
    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part hereof.
     

    Item 4.
    Description of Securities.
     
    Not applicable.
     
    Item 5.
    Interests of Named Experts and Counsel.
     
    Not applicable.
     
    Item 6.
    Indemnification of Directors and Officers.
     
    Set forth below is a description of the General Corporation Law of the State of Delaware (the “DGCL”), the Company’s Certificate of Incorporation and the Company’s Bylaws, as such provisions relate to the indemnification of the Company’s directors and officers. This description is intended only as a summary and is qualified in its entirety by reference to the DGCL, the Company’s Certificate of Incorporation and the Company’s Bylaws.
     
    Section 102(b)(7) of the DGCL generally permits a Delaware corporation to provide in its certificate of incorporation that directors or certain officers of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, except for liability (i) with respect to directors and officers, any breach of the director’s or officer’s duty of loyalty to the corporation or its stockholders; (ii) with respect to directors and officers, acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; (iii) with respect to directors, payments of unlawful dividends or unlawful stock repurchases or redemptions under Section 174 of the DGCL; (iv) with respect to directors and officers, any transaction from which the director or officer derived an improper personal benefit; or (v) with respect to officers, any action by or in the right of the corporation.
     
    Section 145(a) of the DGCL provides, in general, that a Delaware corporation may indemnify any person who is or was a party, or is threatened to be made a party, to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) because that person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or other enterprise. The indemnity may include expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, so long as the person acted in good faith and in a manner he or she reasonably believed was in or not opposed to the corporation’s best interests, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.
     
    Section 145(b) of the DGCL provides, in general, that a Delaware corporation may indemnify any person who is or was a party, or is threatened to be made a party, to any threatened, pending or completed action or suit by or in the right of the corporation to obtain a judgment in its favor because the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or other enterprise. The indemnity may include expenses (including attorneys’ fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action, so long as the person acted in good faith and in a manner the person reasonably believed was in or not opposed to the corporation’s best interests, except that no indemnification shall be permitted without judicial approval if a court has determined that the person is to be liable to the corporation with respect to such claim.
     
    Section 145(c) of the DGCL provides that, if a present or former director or officer has been successful in defense of any action referred to in Sections 145(a) and (b) of the DGCL, the corporation must indemnify such officer or director against the expenses (including attorneys’ fees) he or she actually and reasonably incurred in connection with such action.


    Section 145(g) of the DGCL provides, in general, that a corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or other enterprise against any liability asserted against and incurred by such person, in any such capacity, or arising out of his or her status as such, whether or not the corporation could indemnify the person against such liability under Section 145 of the DGCL.
     
    The Company’s Certificate of Incorporation contains provisions that limit the liability of the Company’s directors and officers for monetary damages to the fullest extent permitted by the DGCL. In addition, if the DGCL is amended to provide for further limitations on the personal liability of directors of corporations, then the personal liability of the Company’s directors and officers will be further limited to the greatest extent permitted by the DGCL.

    The Company’s Bylaws provide that the Company will indemnify its directors and officers, and may indemnify its employees, agents and any other persons, to the fullest extent permitted by the DGCL, subject to limited exceptions. The Company’s Bylaws also provide that the Company must advance expenses incurred by or on behalf of a current or former director or officer in advance of the final disposition of any action or proceeding, subject to limited exceptions.

    Further, the Company has entered into indemnification agreements with each of its directors and executive officers that may be broader than the specific indemnification provisions contained in the DGCL. These indemnification agreements require the Company, among other things, to indemnify its directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require the Company to advance all expenses reasonably and actually incurred by the directors and executive officers in investigating or defending any such action, suit or proceeding. The Company believes that these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers.

    Directors’ and officers’ liability insurance has been purchased for the benefit of the Company’s directors and officers to back up the Company’s indemnification of them against liability incurred in their capacity as directors and officers, subject to certain limitations under applicable law. The Company also maintains insurance policies under which its directors and officers are insured, within the limits and subject to the limitations of those policies, against certain expenses in connection with the defense of, and certain liabilities which might be imposed as a result of, actions, suits, or proceedings to which they are parties by reason of being or having been directors or officers of the Company. The coverage provided by these policies may apply whether or not the Company would have the power to indemnify such person against such liability under the provisions of the DGCL.

    Item 7.
    Exemption from Registration Claimed.
     
    Not applicable.
     
    Item 8.
    Exhibits.
     
    Exhibit
    Number
     
     Description of Document
    3.1
     
    Certificate of Incorporation of Acasti Pharma Inc. (incorporated herein by reference to Exhibit 3.3 to the Company’s Current Report on Form 8-K filed with the Commission on October 7, 2024)
         
    3.2
     
    Bylaws of Acasti Pharma Inc. (incorporated herein by reference to Exhibit 3.4 to the Company’s Current Report on Form 8-K filed with the Commission on October 7, 2024)
         
    4.1
     
    Form of Common Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the Commission on October 7, 2024)
         
    5.1*
     
    Opinion of Hogan Lovells US LLP
         
    10.1
     
    Acasti Pharma Inc. 2024 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Commission on September 30, 2024)


    10.3
     
    Form of 2024 Incentive Stock Option Award Agreement under the Acasti Pharma Inc. 2024 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.3 to the Company’s Registration Statement on Form S-4 filed with the Commission on June 27, 2024)
         
    10.4
     
    Form of 2024 Non-Qualified Stock Option Award Agreement under the Acasti Pharma Inc. 2024 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.4 to the Company’s Registration Statement on Form S-4 filed with the Commission on June 27, 2024)
         
    23.1*
     
    Consent of KPMG LLP, independent registered public accounting firm
         
    23.2*
     
    Consent of Ernst & Young LLP, independent registered public accounting firm
         
    23.3*
     
    Consent of Hogan Lovells US LLP (included in Exhibit 5.1)
         
    24.1*
     
    Power of Attorney (included on signature page hereto)
         
    107*
     
    Filing Fee Table
         
    *
     
    Filed herewith

    Item 9.
    Undertakings.
     
    (a)          The undersigned registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to the registration statement:

    (i)    To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii)    To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” or “Calculation of Registration Fee Table”, as applicable, in the effective registration statement;

    (iii)   To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this registration statement.

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.


    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
     
    (b)          That, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
     
    (c)         Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    SIGNATURES
     
    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Princeton, New Jersey on the 8th day of October, 2024.

     
    ACASTI PHARMA INC.
         
     
    By:
    /s/ Prashant Kohli
     
    Name:
    Prashant Kohli
     
    Title:
    Chief Executive Officer

    POWER OF ATTORNEY
     
    Each person whose signature appears below constitutes and appoints Prashant Kohli his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this Registration Statement and any and all related registration statements necessary to register additional securities, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto such attorney in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that such attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
     
    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated below.

    Name
     
    Title
     
    Date
             
    /s/ Prashant Kohli
      Chief Executive Officer and Director  
    October 8, 2024
    Prashant Kohli
     
    (Principal Executive Officer)
     
             
    /s/ Robert J. DelAversano
     
    Principal Financial Officer
     
    October 8, 2024
    Robert J. DelAversano
     
    (Principal Financial and Principal Accounting Officer)
     
             
    /s/ Vimal Kavuru
     
    Chair of the Board and Director
     
    October 8, 2024
    Vimal Kavuru
       
             
    /s/ Brian Davis
     
    Director
     
    October 8, 2024
    Brian Davis
       
             
    /s/ George Kottayil
     
    Director
     
    October 8, 2024
    George Kottayil
       
             
    /s/ Edward Neugeboren
     
    Director
     
    October 8, 2024
    Edward Neugeboren
       



    Get the next $ACST alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACST

    DatePrice TargetRatingAnalyst
    12/22/2021$6.00Outperform
    Oppenheimer
    12/21/2021$6.00Outperform
    Oppenheimer
    More analyst ratings

    $ACST
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Grace Therapeutics to Participate in Upcoming Investor Events January 2025

      PRINCETON, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) formerly Acasti Pharma Inc. (NASDAQ:ACST) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs, today announced that Chief Executive Officer Prashant Kohli will participate the following investor and industry networking events during the month of January 2025. 14th Annual LifeSci Partners Corporate Access Event – (January 13, 2025) BIO One-on-One Partnering™ – (Ja

      1/7/25 8:00:00 AM ET
      $ACST
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Grace Therapeutics to Exhibit at the American Society of Health-System Pharmacists Conference

      PRINCETON, N.J., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) formerly Acasti Pharma Inc. (NASDAQ:ACST) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs, today announced that the Company will be participating in the mid-year clinical meeting of the American Society of Health-System Pharmacists (ASHP) to be held December 8–12, 2024, in New Orleans, LA. "As we look forward to data readout from our Phase 3 STRIVE-ON trial

      12/4/24 8:00:00 AM ET
      $ACST
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

      Name Change Reflects Extensive Scientific and Corporate Brand Equity Previously Established under Grace Therapeutics Grace Therapeutics will begin trading on Nasdaq under the trading symbol "GRCE" effective October 28, 2024 Virtual Key Opinion Leader Event to be held on November 20th PRINCETON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTx-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that it is changing its name to Grace Therapeutics, Inc. (Grace Therapeutics).

      10/25/24 8:00:00 AM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Acasti Pharma with a new price target

      Oppenheimer initiated coverage of Acasti Pharma with a rating of Outperform and set a new price target of $6.00

      12/22/21 5:05:43 AM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Acasti Pharma with a new price target

      Oppenheimer initiated coverage of Acasti Pharma with a rating of Outperform and set a new price target of $6.00

      12/21/21 4:57:37 PM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACST
    SEC Filings

    See more
    • Acasti Pharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Grace Therapeutics, Inc. (0001444192) (Filer)

      10/28/24 8:22:47 AM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acasti Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Acasti Pharma Inc. (0001444192) (Filer)

      10/25/24 8:13:49 AM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Acasti Pharma Inc.

      EFFECT - Acasti Pharma Inc. (0001444192) (Filer)

      10/16/24 12:15:09 AM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACST
    Financials

    Live finance-specific insights

    See more
    • Acasti Pharma Reports Third Quarter 2023 Operational Results

      Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced financial and operational results for the third quarter ended December 31, 2022 Recent Highlights The Company anticipates receiving clarifying guidance from the Food and Drug Administration (FDA) on its proposed phase 3 study design for GTX-104 through a written Type C meeting in the first calendar quarter of 2023. The Company expects that favorable FDA guidance would allow Acasti

      2/14/23 7:00:00 AM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023

      Call to be held on Tuesday, February 14th at 1:00 PM Eastern Time LAVAL, QB, Feb. 7, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that it will host a conference call at 1:00 PM Eastern Time on Tuesday, February 14, 2023, to discuss the Company's corporate progress and other developments, as well as financial results for third quarter 2023 ended December 31, 2022. The conference call will be a

      2/7/23 9:00:00 AM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures

      LAVAL, Québec, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that it will host a conference call on Tuesday, January 10, 2023 at 4:30 p.m. ET to review the recently reported preliminary topline results from two separate Phase 1 pharmacokinetic (PK) studies for GTX-101 and GTX-102. Both studies successfully met all target outcome measures. The conference call will be available via telephone by dialing toll free 844-836-8745 for U.S. callers or +1 412-317-6797 for international callers. A webca

      1/5/23 9:00:00 AM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: New insider Adar1 Capital Management, Llc claimed ownership of 959,571 shares (SEC Form 3)

      3/A - Acasti Pharma Inc. (0001444192) (Issuer)

      7/11/24 11:16:42 AM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Adar1 Capital Management, Llc claimed ownership of 959,571 shares (SEC Form 3)

      3 - Acasti Pharma Inc. (0001444192) (Issuer)

      7/9/24 8:29:48 PM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by D'Andrea Carrie (Amendment)

      4/A - Acasti Pharma Inc. (0001444192) (Issuer)

      5/10/24 4:11:36 PM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACST
    Leadership Updates

    Live Leadership Updates

    See more

    $ACST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Acasti Announces Appointment of New Scientific Advisory Board Members

      LAVAL, QC, June 22, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced the appointment of W. Taylor Kimberly, MD, PhD, Alejandro A. Rabinstein, MD and Sherry H-Y. Chou, MD to its Scientific Advisory Board. "We are extremely pleased to add eminent physicians with a deep understanding of aSAH and neurocritical care to the Acasti Scientific Advisory Board," commented Prashant Kohli, CEO of Acasti. "As we continue to focus our efforts squarely on the advanc

      6/22/23 9:00:00 AM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acasti Announces Appointment of Prashant Kohli as CEO

      LAVAL, QC, April 4, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST), a late-stage specialty pharma company advancing drug candidates for rare and orphan diseases, today announced the appointment of Prashant Kohli as Acasti's new Chief Executive Officer, succeeding Jan D'Alvise. The parties have mutually agreed to part ways, and Ms. D'Alvise will be stepping down from the board. Prashant Kohli has served as Chief Commercial Officer of Acasti since 2022. Mr. Kohli has over 20 years of commercialization experience leading strategy, sales, marketing, and product management. Recently, Mr. Kohli was VP, Commercial Operations of Acasti and at Grace Therapeutics, p

      4/4/23 8:00:00 AM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders

      LAVAL, Québec, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announced today the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") which was held virtually on Wednesday September 28, 2022. Election of Directors All five (5) nominees listed in the proxy statement dated August 31, 2022 (the "Proxy Statement"), being Jean Marie (John) Canan, Jan D'Alvise, Donald Olds, Vimal Kavuru and Michael L. Derby were elected as directors of Acasti at the Meeting to serve for a te

      9/29/22 9:00:00 AM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Acasti Pharma Inc.

      SC 13G - Acasti Pharma Inc. (0001444192) (Subject)

      7/10/24 9:10:22 PM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Acasti Pharma Inc.

      SC 13G - Acasti Pharma Inc. (0001444192) (Subject)

      4/9/24 8:46:48 AM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Acasti Pharma Inc.

      SC 13G - Acasti Pharma Inc. (0001444192) (Subject)

      2/13/24 7:03:33 PM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Kavuru Vimal bought $1,249,934 worth of shares (676,371 units at $1.85) (SEC Form 4)

      4 - Acasti Pharma Inc. (0001444192) (Issuer)

      9/27/23 7:46:45 PM ET
      $ACST
      Biotechnology: Pharmaceutical Preparations
      Health Care